Additionally, due to the mild phenotype observed in children with Finnish founder variants, Finnish pediatric cardiologists suggest children with KCNH2 founder variants start beta-blockers later in childhood but before the onset of puberty, provided their QTc is below 470 ms and there is no family history of cardiac arrest (24). The gene discussed is KCNH2; the disease is cardiac arrest.